1. Home
  2. NOMA vs NSPR Comparison

NOMA vs NSPR Comparison

Compare NOMA & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NOMA

NOMADAR Corp.

N/A

Current Price

$3.38

Market Cap

65.4M

ML Signal

N/A

Logo InspireMD Inc.

NSPR

InspireMD Inc.

HOLD

Current Price

$0.74

Market Cap

72.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NOMA
NSPR
Founded
2023
2005
Country
United States
United States
Employees
8
N/A
Industry
Services-Misc. Amusement & Recreation
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
65.4M
72.1M
IPO Year
N/A
2009

Fundamental Metrics

Financial Performance
Metric
NOMA
NSPR
Price
$3.38
$0.74
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
7.8K
171.4K
Earning Date
05-22-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,310,000.00
Revenue This Year
N/A
$57.98
Revenue Next Year
N/A
$95.41
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.55
$0.69
52 Week High
$10.00
$2.93

Technical Indicators

Market Signals
Indicator
NOMA
NSPR
Relative Strength Index (RSI) 51.00 30.08
Support Level $3.30 N/A
Resistance Level $3.90 $1.04
Average True Range (ATR) 0.26 0.10
MACD 0.01 -0.00
Stochastic Oscillator 59.09 12.86

Price Performance

Historical Comparison
NOMA
NSPR

About NOMA NOMADAR Corp.

Nomadar Corp operates at the intersection of sports and technology, focusing on high-performance training programs and cultural exchange. The company aims to connect athletes, coaches, and fans through inventive technological solutions, enhancing sports development beyond physical borders. It offers services like the High Performance Training (HPT) program and promotes the legacy of iconic athletes. The Company generates revenue through its High Performance Training Program and events management at the JP Financial Stadium.

About NSPR InspireMD Inc.

InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.

Share on Social Networks: